Who buys BeiGene (bgne)?
BGNE stock was purchased by a variety of institutional investors in the last quarter, including Segantii Capital Management Ltd, Crossmark Global Holdings Inc., Sumitomo Mitsui DS Asset Management Company Ltd, and Cutler Group LP. Company insiders that have bought BeiGene stock in the last two years include Amgen Inc, and Ltd Beigene.
Where can I buy shares of bgne?
Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
How much of BeiGene's stock is owned by institutions?
54.78% of the stock of BeiGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Earnings for BeiGene are expected to decrease in the coming year, from ($12.64) to ($14.23) per share.
What happened to bgne?
(BGNE) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.
Is BeiGene stock a Buy, Sell or Hold?
BeiGene stock has received a consensus rating of buy. The average rating score is and is based on 19 buy ratings, 2 hold ratings, and 1 sell ratings.
What was the 52-week low for BeiGene stock?
The low in the last 52 weeks of BeiGene stock was 118.22. According to the current price, BeiGene is 130.75% away from the 52-week low.
What was the 52-week high for BeiGene stock?
The high in the last 52 weeks of BeiGene stock was 426.05. According to the current price, BeiGene is 36.28% away from the 52-week high.
What are analysts forecasts for BeiGene stock?
The 22 analysts offering price forecasts for BeiGene have a median target of 324.09, with a high estimate of 431.00 and a low estimate of 177.00. T...
About BeiGene
BeiGene (NASDAQ:BGNE) Frequently Asked Questions
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V.
What is Beigene valuation?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BeiGene stock. View analyst ratings for BeiGene or view top-rated stocks.
What is Beigene Pharmaceuticals?
A valuation method that multiplies the price of a company's stock by the total number of outstanding shares. BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment.
Where is Beigene located?
About. . BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. Founded in Beijing in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in China, the United States, Australia and Europe. BeiGene has developed several pharmaceuticals, including tislelizumab, ...
What is Beigene 2021?
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. Founded in Beijing in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in China , the United States, Australia and Europe.